| Literature DB >> 25022283 |
Qi-Long Chen, Yu Pan, Jia-Qin Cai, Di Wu, Ke Chen, Yi-Ping Mou1.
Abstract
BACKGROUND: In past decades, laparoscopic surgery has been introduced for the treatment of gastrointestinal stromal tumors (GISTs). Recently, additional studies comparing laparoscopic versus open surgery for gastric GISTs have been published, and an updated meta-analysis of this subject is necessary.Entities:
Mesh:
Year: 2014 PMID: 25022283 PMCID: PMC4123825 DOI: 10.1186/1477-7819-12-206
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Figure 1Flow chart of literature search strategies. GIST, gastrointestinal stromal tumor.
Summary of studies included in the meta-analysis
| Shimizu | Japan | OCS (R) | 2002 | 1986-2000 | 11 | 8 | 0 | NR | NR | NR | NR | 7 |
| Matthews | USA | OCS (R) | 2002 | 1994-2000 | 21 | 12 | NR | 20 | 18 | 1 | 1 | 7 |
| Ishikawa | Japan | OCS (R) | 2006 | 1993-2004 | 14 | 7 | NR | 60 (5 to 119) | 61 (3 to 130) | 2 | 1 | 8 |
| Mochizuki | Japan | OCS (R) | 2006 | 2000-2004 | 12 | 10 | NR | 26 (6 to 53) | NR | 0 | 0 | 8 |
| Nishimura | Japan | OCS (R) | 2007 | 1993-2004 | 39 | 28 | 2.6 | 18.9 (2.6 to 96.4) | 31.2 (4.4 to 121.9) | 1 | 4 | 9 |
| Pitsinis | UK | OCS (P) | 2007 | 2004-2006 | 6 | 7 | NR | 9 | 9 | 0 | 0 | 6 |
| Catena | Italy | OCS (P) | 2008 | 1995-2006 | 21 | 25 | NR | 35 (5 to 58) | 91 (80 to 136) | 0 | 1 | 9 |
| Silberhumer | Austria | OCS (R) | 2009 | 1998-2006 | 22 | 41 | 18.2 | 30 ± 20 | 41 ± 31 | 0 | 4 | 8 |
| Goh | Singapore | OCS (R) | 2010 | 2001-2009 | 14 | 39 | 7.1 | 8 (3 to 60) | 21(2 to 72) | 0 | 2 | 7 |
| Karakousis | USA | OCS (P) | 2011 | 1998-2009 | 40 | 40 | 22.5 | 28 (0.3 to 70) | 43 (0.1 to 139) | 1 | 1 | 9 |
| Dai | China | OCS (R) | 2011 | 2000-2009 | 18 | 30 | NR | 78 | 64 | 2 | 3 | 9 |
| De Vogelaere | Belgium | OCS (P) | 2012 | 1997-2011 | 37 | 16 | NR | 83 (2 to 163) | 71 (0.3 to 199) | 0 | 6 | 8 |
| Melstrom | USA | OCS (P) | 2012 | 1999-2008 | 17 | 29 | 5.9 | 32 | 59 | 0 | 4 | 7 |
| Lee | Korea | OCS (R) | 2011 | 2001-2008 | 50 | 50 | 2 | 21.1 (0 to 64) | 22.3 (0 to 93) | 0 | 0 | 9 |
| Wan | China | OCS (R) | 2012 | 2004-2011 | 68 | 88 | NR | 29 (4 to 89) | 36 (4 to 90) | 3 | 4 | 9 |
| Pucci | USA | OCS (P) | 2012 | 2002-2012 | 57 | 47 | 1.8 | NR | NR | NR | | 7 |
| Kim | Korea | OCS (R) | 2012 | 1998-2011 | 24 | 14 | NR | 62.6 (8.9 to 164.4) | 58.3 (18.8 to 123.2) | 1 | 3 | 7 |
| Shu | China | OCS (R) | 2013 | 2010-2012 | 15 | 21 | NR | NR | NR | N | NR | 8 |
| Lee | Taiwan | OCS (R) | 2013 | 2007-2009 | 30 | 32 | NR | NR | NR | NR | NR | 8 |
| Kasetsermwiriya | Japan | OCS (R) | 2014 | 1988-2011 | 23 | 10 | NR | 46 (2 to 168) | 19 (1 to 275) | 0 | 1 | 8 |
| Lin | China | OCS (R) | 2014 | 2007-2012 | 23 | 23 | 4.3 | 34 (6 to 78) | 2 | 3 | 9 | |
| Takahashi | Japan | OCS (R) | 2014 | 1995-2011 | 12 | 15 | 25 | 57 (7 to 120) | 69 (13 to 154) | 1 | 2 | 8 |
LAP, laparoscopic surgery; NR, not reported; OCS, observational clinical study; OPEN, open surgery; P, prospectively collected data; R, retrospectively collected data.
Figure 2Meta-analysis of the pooled data: tumor size (cm).
Figure 3Meta-analysis of the pooled data: operation time (minutes).
Figure 4Meta-analysis of the pooled data: intraoperative blood loss (ml).
Figure 5Meta-analysis of the pooled data: time to first flatus (days).
Figure 6Meta-analysis of the pooled data: time to oral intake (days).
Figure 7Meta-analysis of the pooled data: hospital stay (days).
Figure 8Meta-analysis of the pooled data: overall complications.
Figure 9Meta-analysis of the pooled data: recurrences.
Summary of the available data about recurrence patterns and survival outcomes
| [ | LAP | High | NR | Dead | [ | OPEN | NR | NR | Dead | [ | OPEN | High | 6 m Liver | 52 m Alivea |
| [ | OPEN | High | NR | 14 m Dead | [ | OPEN | High | Local | Deadb | [ | OPEN | High | 9 m Liver | 75 m Alivea |
| [ | LAP | High | Liver | 32 m Dead | [ | OPEN | High | Local | Alivea | [ | OPEN | High | 21 m Liver | 16y Deada |
| [ | OPEN | High | Liver | 9 m Dead | [ | OPEN | High | Liver | Alivea | [ | OPEN | High | 52 m Peritoneal | Deada |
| [ | LAP | Low | Local | Alive | [ | OPEN | High | Multiple | Alivea | [ | OPEN | High | 60 m Liver | Alive |
| [ | LAP | Low | 33 m Local | Alive | [ | LAP | High | Peritoneal | 4 y Alive | [ | OPEN | High | 6 m Colon | Deada |
| [ | OPEN | High | 7 m Peritoneal | Alive | [ | OPEN | Moderate | Liver | 10 y Alive | [ | LAP | High | 31 m Stomach | Alive |
| [ | OPEN | High | 53 m Local | Alive | [ | OPEN | High | 4 m Liver | 28 m Deada | [ | OPEN | High | 15 Peritoneal | Deada |
| [ | OPEN | High | 37 m Liver | Alive | [ | OPEN | High | 10 m Liver | Alivea | [ | OPEN | High | 11 m Liver | 59 m Alive |
| [ | OPEN | High | 15 m Multipled | Alive | [ | OPEN | High | 42 m Liver | 46 m Deada,c |
LAP, laparoscopic surgery; m: month; NR, not reported; OPEN, open surgery; y: year.
atreated with imatinib; bdue to cardiac insufficiency; cdue to lung cancer; dincluded liver and local recurrence.
Pooled outcomes of subgroup analysis for studies of wedge resection
| Operation time (min) | 8 | 203 | 233 | <0.001, 82% | WMD = 12.03 | -8.03, 32.09 | 0.24 |
| Blood loss (ml) | 5 | 118 | 151 | 0.03, 64% | WMD = -48.29 | -78.23, -18.36 | <0.01 |
| Time to first flatus (d) | 6 | 119 | 144 | 0.10, 46% | WMD = -1.35 | -1.66, -1.03 | <0.01 |
| Time to oral intake (d) | 7 | 182 | 208 | 0.001, 73% | WMD = -1.67 | -2.19, -1.15 | <0.01 |
| Hospital stay (d) | 8 | 203 | 233 | 0.002, 68% | WMD = -2.53 | -3.50, -1.57 | <0.01 |
| Overall complications | 8 | 203 | 233 | 0.70, 0% | RR = 0.47 | 0.22, 1.01 | 0.05 |
| Tumor size (cm) | 8 | 203 | 233 | 0.10, 42% | WMD = -0.77 | -1.23, -0.31 | <0.01 |
| Recurrence | 5 | 130 | 165 | 0.95, 0% | RR = 1.01 | 0.39, 2.63 | 0.99 |
CI, confidence interval; LAP, laparoscopic surgery; OPEN, open surgery; RR, risk ratio; WMD, weighted mean difference.
Pooled outcomes of subgroup analysis for studies with comparable tumor size or risk index
| Operation time (min) | 13 | 371 | 377 | <0.001, 81% | WMD = -1.06 | -16.93, 14.81 | 0.90 |
| Blood loss (ml) | 11 | 300 | 302 | <0.001, 71% | WMD = -58.20 | -81.76, -34.65 | <0.01 |
| Time to first flatus (d) | 6 | 129 | 142 | 0.09, 47% | WMD = -1.28 | -1.60, -0.97 | <0.01 |
| Time to oral intake (d) | 7 | 212 | 241 | 0.02, 61% | WMD = -1.77 | -2.18, -1.35 | <0.01 |
| Hospital stay (d) | 11 | 309 | 339 | 0.006, 60% | WMD = -2.87 | -3.54, -2.21 | <0.01 |
| Overall complications | 12 | 341 | 345 | 0.74, 0% | RR = 0.49 | 0.30, 0.81 | <0.01 |
| Tumor size (cm) | 13 | 371 | 377 | 0.23, 21% | WMD = -0.57 | -0.86, -0.29 | <0.01 |
| Recurrence | 8 | 248 | 232 | 0.81, 0% | RR = 0.66 | 0.31, 1.42 | 0.29 |
CI, confidence interval; LAP, laparoscopic surgery; OPEN, open surgery; RR, risk ratio; WMD, weighted mean difference.
Figure 10Funnel plot of the overall postoperative complications.